The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission

The Effect of Continuous, Various Dosages of Furosemide Drip on Hearing as Measured by Acoustic Emission

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00945386

Enrollment

Registered

2009-07-24

Start date

2009-08-31

Completion date

2010-08-31

Last updated

2009-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Status

Keywords

children, critically ill, furosemide, acoustic emission

Brief summary

Pediatric patients, during their illness often treated with furosemide (Lasix) continuous drip, often, with dosages above 4-6mg/kg/day (the recommended dose). This study will monitor hearing status of these children prior to their therapy with furosemide, during this therapy and after.

Detailed description

This study will record hearing status, by acoustic emission, of critically ill children, treated with different dosages of furosemide drip. Acoustic emission test will be done prior to therapy and q48 hours during their course of treatment with furosemide drip. Dosage of furosemide drip, boluses and other relevant medications (i.e - vancomycin, muscular relaxants, aminoglycosides etc) will be recorded.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Months to 18 Years

Healthy volunteers

Inclusion criteria

* All children admitted to Pediatric ICU who are treated with furosemide continuous drip.

Exclusion criteria

* Children with known hearing abnormalities prior to treatment.

Countries

Israel

Contacts

Primary ContactElhanan - Nahum, MD

enahum@clalit.org.il972 3 9253686

Backup ContactMiriam Davidowitz, MD

972 3 7253666

Outcome results